17 recruiting. 17 Phase 2, 5 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Recruiting 17 |
| Phase 1 | 5 | Recruiting 5 |
| Phase 3 | 3 | Recruiting 3 |
Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa ENERGI-F703EB Cream, Matched vehicle cream - Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa | Phase 2 | Recruiting | Energenesis Biomedical Co., Ltd. | 24 | 2026-10-08 | 2026-10-05 |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study TCP-25 gel, Vehicle (placebo) - Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa | Phase 2 | Recruiting | Xinnate AB | 32 | 2026-01-30 | 2026-11-02 |
| GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment Genetically Modified Epidermolysis Bullosa Self-Assembled Skin Substitute (GMEB-SASS) - RDEB, Recessive Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Recruiting | CHU de Quebec-Universite Laval | 9 | 2026-01-07 | 2026-03-18 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex 5% TolaSure Topical Gel, Topical Placebo Gel - Epidermolysis Bullosa Simplex | Phase 2 | Recruiting | BioMendics, LLC | 40 | 2025-09-11 | 2026-08-13 |
| Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa Immunoglobulin G - Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita | Phase 1 / Phase 2 | Recruiting | M. Peter Marinkovich | 8 | 2025-08-04 | 2026-05-05 |
| A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT Hemopfin+Green Light, Vehicle+Green Light - Port-wine Birthmarks, Port-Wine Stain | Phase 2 | Recruiting | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 84 | 2024-09-21 | 2026-03-03 |
| MSC EVs in Dystrophic Epidermolysis Bullosa AGLE-102 - Dystrophic Epidermolysis Bullosa | Phase 1 / Phase 2 | Recruiting | Aegle Therapeutics | 8 | 2024-08-13 | 2025-06-25 |
| A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized Apremilast treatment - Epidermolysis Bullosa Simplex, Genodermatosis | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Nice | 20 | 2024-08-06 | 2025-02-24 |
| Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa Ev.FV 1.0 x 1011 par/ml - Dystrophic Epidermolysis Bullosa, Wound Heal | Phase 1 / Phase 2 | Recruiting | Isfahan University of Medical Sciences | 20 | 2024-01-09 | 2025-11-17 |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 20 | 2023-03-14 | 2026-08-31 |
| Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal Dysplasia ER004 - X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) | Phase 2 | Recruiting | EspeRare Foundation | 20 | 2022-04-26 | 2025-04-30 |
| Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures Alemtuzumab, Fludarabine, Melphalan - Primary Immune Deficiency Disorder, Immune Deficiency Disease | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 27 | 2020-02-12 | 2025-11-28 |
| Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU) - Fanconi Anemia, Severe Aplastic Anemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 48 | 2018-11-13 | 2026-01-30 |
| Gentamicin for Junctional Epidermolysis Bullosa Gentamicin Sulfate - Junctional Epidermolysis Bullosa | Phase 1 / Phase 2 | Recruiting | University of Southern California | 6 | 2018-06-01 | 2020-04-07 |
| Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT Hydroxyurea, Alemtuzumab, Fludarabine - Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes | Phase 2 | Recruiting | Paul Szabolcs | 100 | 2014-02-04 | 2025-12-15 |
Epidermolysis Bullosa Dystrophica (6) · Epidermolysis Bullosa (5) · Dyskeratosis Congenita (3) · Epidermolysis Bullosa Simplex (3) · Epidermolysis Bullosa, Junctional (3) · Netherton Syndrome (3) · Bone Marrow Failure Disorders (2) · Fanconi Anemia (2) · Primary Immunodeficiency Diseases (2) · Skin Diseases (2) · Skin Diseases, Genetic (2) · Adrenoleukodystrophy (1) · Anemia, Aplastic (1) · Anemia, Diamond-Blackfan (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17) · Congenital Abnormalities (16) · Skin and Connective Tissue Diseases (16) · Genetic Diseases, Inborn (15) · Skin Diseases (15) · Skin Diseases, Genetic (14) · Skin Diseases, Vesiculobullous (8) · Connective Tissue Diseases (6) · Collagen Diseases (5) · Abnormalities, Multiple (4) · Epidermolysis Bullosa (4) · Genetic Diseases, X-Linked (4) · Infant, Newborn, Diseases (4) · Anemia (3)
Alemtuzumab (3) · Melphalan (3) · fludarabine (3) · Cyclophosphamide (2) · Whole-Body Irradiation (2) · Busulfan (1) · Gentamicins (1) · Granulocyte Colony-Stimulating Factor (1) · Hydroxyurea (1) · Immunoglobulin G (1) · Methylprednisolone (1) · Mycophenolic Acid (1) · Rituximab (1) · Tacrolimus (1) · Thiotepa (1)
Quoin Pharmaceuticals (3) · Aegle Therapeutics (1) · BioMendics, LLC (1) · CHU de Quebec-Universite Laval (1) · Centre Hospitalier Universitaire de Nice (1) · Energenesis Biomedical Co., Ltd. (1) · EspeRare Foundation (1) · Isfahan University of Medical Sciences (1) · M. Peter Marinkovich (1) · Masonic Cancer Center, University of Minnesota (1) · Paul Szabolcs (1) · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Southern California (1) · Xinnate AB (1)
United States (13) · France (3) · Italy (2) · Spain (2) · United Kingdom (2) · Canada (1) · Germany (1) · Greece (1) · Iran (1) · Poland (1) · Sweden (1) · Taiwan (1)
David T Woodley, MD (1) · Elena Pope, MD, FRCPC (1) · Heather J Symons, MD, MHS (1) · Holm Schneider, MD (1) · Lucie Germain, PhD (1) · Margaret MacMillan, MD, Msc, FRCPC (1) · Masoud Soleimani, Prof (1) · Matt P Marinkovich, MD (1) · Paul Szabolcs, MD (1) · Tony Andrasfay (1)
PMID 32634238, PMID 32750127, PMID 33159275, PMID 35234826, PMID 41224305
2023 (1)